New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 5, 2013
08:09 EDTBOTABiota Pharmaceuticals initiates dosing in Phase 2 IGLOO trial of LANI
Biota Pharmaceuticals announced that it has commenced dosing patients in the Northern Hemisphere portion of its ongoing Phase 2, randomized, double blind, placebo controlled, parallel arm clinical trial of laninamivir octanoate, or LANI. The trial, referred to as "IGLOO", compares the safety and efficacy of 40 mg and 80 mg of LANI with placebo, all delivered by a TwinCaps inhaler in adults with presumed influenza A or B infection. The trial was initiated in the Southern Hemisphere in June and is now continuing in multiple countries in the Northern Hemisphere. The company's goal is to complete enrollment in the IGLOO trial by the end of the influenza season in the Northern Hemisphere and have top-line data available in mid-2014. IGLOO is being conducted in connection with the company's contract with the U.S. Office of Biomedical Advanced Research and Development Authority.
News For BOTA From The Last 14 Days
Check below for free stories on BOTA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for BOTA

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use